Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?

Journal of Thoracic and Cardiovascular Surgery

Volumn 138, Issue 2, 2009, Pages 439-445

  Ohba, Yasuomi ^a   Nomori, Hiroaki ^a,c   Mori, Takeshi ^a   Ikeda, Koei ^a   Shibata, Hidekatsu ^a   Kobayashi, Hironori ^a   Shiraishi, Shinya ^a   Katahira, Kazuhiro ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO CHUO HOSPITAL   (Japan)

^c Institute of DNA Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG LESION; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 67651094017     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.12.026     Document Type: Article

References (31)

1. Wang J., Takashima S., Takayama F., Kawakami S., Saito A., Matsushita T., et al. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220 (2001) 621-630
2. Sumi M., Takagi Y., Uetani M., Morikawa M., Hayashi K., Kabasawa H., et al. Diffusion-weighted echoplanar MR imaging of salivary glands. AJR Am J Roentgenol 178 (2002) 959-965
3. Takahara T., Imai Y., Yamashita T., Yasuda S., Nasu S., and Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22 (2004) 275-282
4. Nasu K., Kuroki Y., Kuroki S., Murakami K., Nawano S., and Moriyama N. Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol 34 (2004) 620-626
5. Murakami R., Sugahara T., Nakamura H., Hirai T., Kitajima M., Hayashida Y., et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 243 (2007) 493-499
6. Woodhams R., Matsunaga K., Kan S., Hata H., Ozaki M., Iwabuchi K., et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 4 (2005) 35-42
7. Hayashida Y., Yakushiji T., Awai K., Katahira K., Nakayama Y., Shimomura O., et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16 (2006) 2637-2643
8. Reinsberg S.A., Payne G.S., Riches S.F., Ashley S., Brewster J.M., Morgan V.A., et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 188 (2007) 91-98
9. Dzik-Jurasz A., Domenig C., George M., Wolber J., Padhani A., Brown G., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360 (2002) 307-308
10. Matoba M., Tonami H., Kondou T., Yokota H., Higashi K., Toga H., et al. Lung carcinoma: diffusion weighted MR imaging-preliminary evaluation with apparent diffusion coefficient. Radiology 243 (2007) 570-577
11. Komori T., Narabayashi I., Matsumura K., Matsuki M., Akagi H., Ogura Y., et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 21 (2007) 209-215
12. Lichy M.P., Aschoff P., Plathow C., Stemmer A., Horger W., Mueller-Horvat C., et al. Tumor detection by diffusion-weighted MRI and ADC-mapping. Initial clinical experiences in comparison to PET-CT. Invest Radiol 42 (2007) 605-613
13. Mori T., Nomori H., Ikeda K., Kawanaka K., Shiraishi S., Katahira K., et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses. J Thorac Oncol 3 (2008) 358-364
14. Ohno Y., Koyama H., Onishi Y., et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248 (2008) 643-654
15. Cerfolio R.J., Bryant A.S., Ohja B., and Bartolucci A.A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130 (2005) 151-159
16. Nomori H., Watanabe K., Ohtsuka T., Naruke T., Suemasu K., Kobayashi T., et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. J Thorac Cardiovasc Surg 128 (2004) 396-401
17. Ohtsuka T., Nomori H., Watanabe K., Kaji M., Naruke T., Suemasu K., et al. Prognostic significance of [18F] fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 107 (2006) 2468-2473
18. Watanabe K., Nomori H., Ohtsuka T., Naruke T., Ebihara A., Orikasa H., et al. [F-18] Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 36 (2006) 403-409
19. Menda Y., Bushnell D.L., Madsen M.T., McLaughlin K., Kahn D., and Kernstine K.H. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl Med Commun 22 (2001) 1077-1081
20. Nomori H., Watanabe K., Ohtsuka T., Naruke T., Suemasu K., and Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3cm in diameter, with special reference to CT images. Lung Cancer 45 (2004) 19-27
21. Nomori H., Watanabe K., Ohtsuka T., Naruke T., Suemasu K., and Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1cm to 3cm in size. Ann Thorac Surg 79 (2005) 984-988
22. Koh D.M., and Padhani A.R. Diffusion-weighted MRI: a new functional clinical technique for tumor imaging. Br J Radiol 79 (2006) 633-635
23. Sobin L.W., and Witteking C.H. UICC TMN classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York p. 131-41
24. Bréchot J.M., Chevret S., Charpentier M.C., Appere de Vecchi C., Capron F., Prudent J., et al. Blood vessel and lymphatic vessel invasion in resected non-small cell lung carcinoma. Cancer 78 (1996) 2111-2118
25. Takise A., Kodama T., Shimosato Y., Watanabe S., and Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 61 (1988) 2083-2088
26. Atalay M.K., Poncelet B.P., Kantor H.L., Brady T.J., and Weisskoff R.M. Cardiac susceptibility artifacts arising from the heart-lung interface. Magn Reson Med 45 (2001) 341-345
27. Chen B.T., Yordanov A.T., and Johnson G.A. Ventilation-synchronous magnetic resonance microscopy of pulmonary structure and ventilation in mice. Magn Reson Med 53 (2005) 69-75
28. Kim C.K., Gupta N.C., Chandramouli B., and Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 35 (1994) 164-167
29. Lindholm P., Minn H., Leskinen-Kallio S., Bergman J., Ruotsalainen U., and Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 34 (1993) 1-6
30. Obrzut S., Pham R.H., Vera D.R., Badran K., and Hoha C.K. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET. Nucl Med 27 (2007) 7-13
31. Nomori H., Mori T., Ikeda K., Kawanaka K., Shiraishi S., Katahira K., et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 135 (2008) 816-822